Core Viewpoint - Wealthfront Corporation is set to release its third-quarter earnings on January 12, 2025, with expectations of earnings at 15 cents per share and revenue of $93.23 million [1] Group 1: Earnings and IPO - Wealthfront's third-quarter earnings are anticipated to be 15 cents per share on revenue of $93.23 million [1] - The company priced its initial public offering at $14.00 per share for 34,615,384 common shares [1] - Following the IPO pricing, Wealthfront's shares fell by 0.8% to close at $13.50 [1] Group 2: Analyst Ratings - JP Morgan analyst Kenneth Worthington initiated coverage with an Overweight rating and a price target of $16 [3] - RBC Capital analyst Daniel Perlin initiated coverage with an Outperform rating and a price target of $17 [3] - Citizens analyst Devin Ryan initiated coverage with a Market Outperform rating and a price target of $20 [3] - Keybanc analyst Alex Markgraff initiated coverage with a Sector Weight rating [3]

Jonathan Siegmann from Stifel Nicolaus set a price target of $220 for NYSE:LDOS, indicating a potential upside of approximately 11.9%.Leidos holds a Zacks Rank of #2 (Buy), suggesting a more favorable outlook compared to ServiceNow's #3 (Hold).The company's market capitalization stands at approximately $25.14 billion, with a trading volume of 1,145,193 shares on the NYSE.Leidos Holdings, Inc. (NYSE:LDOS) is a prominent player in the Computers - IT Services sector, providing technology and engineering servic ...

Core Viewpoint - SouthState Bank Corporation (NYSE: SSB) is recognized as a leading financial institution in the U.S., offering a wide range of banking services and competing effectively in the industry [1] Group 1: Analyst Ratings and Price Targets - Raymond James reaffirmed a "Strong Buy" rating for SouthState Bank and increased its price target from $110 to $115, aligning with a "Moderate Buy" consensus from sixteen research firms [2] - The average one-year price target for SouthState Bank is approximately $115, with Barclays adjusting its target from $125 to $122 while maintaining an "overweight" rating [3] - National Bankshares has set a target price of $127 for SouthState Bank, reflecting strong confidence in its future performance [3] Group 2: Stock Performance and Market Metrics - The current stock price for SSB is $97.12, showing an increase of 1.64% or $1.57, with a trading range today between $95.13 and $97.16 [4] - Over the past year, SSB has experienced a high of $109.64 and a low of $77.74, indicating market volatility [4] - SouthState Bank has a market capitalization of approximately $9.76 billion and a trading volume of 454,916 shares on the NYSE, demonstrating its robust financial standing [5] - Cowen has initiated coverage on SouthState Bank with a "buy" rating, further supporting a positive outlook for the stock [5]

With a market cap of $31.2 billion, Willis Towers Watson Public Limited Company (WTW) is a global advisory, broking and solutions firm. It helps organizations manage risk, design employee benefits, and improve retirement and investment outcomes. While the company is based in London, it operates in more than 140 countries and serves corporations, insurers and institutional clients. Willis Towers Watson is expected to release its fiscal Q4 2025 earnings results shortly. Ahead of this event, analysts expect ...

Core Viewpoint - Saratoga Investment Corp. is expected to report a decline in quarterly earnings and revenue for its third quarter, indicating potential challenges ahead for the company [1]. Financial Performance - The company is projected to report earnings of 59 cents per share for the third quarter, a decrease from 90 cents per share in the same period last year [1]. - Revenue is anticipated to be $31.35 million, down from $35.88 million a year earlier [1]. Recent Developments - On November 6, Saratoga Investment announced a new $85 million credit facility with Valley National Bank, which may provide additional liquidity for operations [2]. - Following the announcement, shares of Saratoga Investment rose by 0.2%, closing at $23.07 [2]. Analyst Ratings - Analyst John Rowan from Janney Montgomery Scott downgraded the stock from Buy to Neutral on October 10, 2025, with an accuracy rate of 51% [3]. - Analyst Casey Alexander from Compass Point also downgraded the stock from Buy to Neutral and reduced the price target from $25.25 to $24.25 on June 9, 2025, with an accuracy rate of 66% [3].

Shares of Market Vectors Indian Rupee/USD ETN (NYSEARCA:INR – Get Free Report) traded down 3.9% on Wednesday . The stock traded as low as $14.61 and last traded at $14.61. 36,601 shares traded hands during trading, a decline of 90% from the average session volume of 349,164 shares. The stock had previously closed at $15.20. Get Market Vectors Indian Rupee/USD ETN alerts: Wall Street Analyst Weigh InSeveral research analysts have commented on the company. Citigroup lowered their target price on Market Vector ...

Navan’s platform is described as more than just a booking tool, but an all-in-one, one-stop shop for business travel needs. Companies can tap into a global inventory of airlines and hotels, including major carriers like Delta, United, and Air France, as well as smaller carriers like RyanAir and Easy Jet, supplemented by such names as Marriot hotels and Budget car rentals. The platform also allows users to select their hotels and control their hotel spending, keeping their travel expenses on target.Few areas ...

Core Viewpoint - Assurant, Inc. is a global provider of risk management solutions, focusing on housing and lifestyle markets, and competes with other firms in the insurance and risk management sector [1] Group 1: Analyst Ratings and Price Targets - Piper Sandler maintains an "Overweight" rating for Assurant, raising its price target from $252 to $264, indicating confidence in the company's future performance [2][6] - Assurant has received an average recommendation of "Moderate Buy" from ten research firms, with eight analysts recommending buying the stock and two suggesting holding it, reflecting general optimism [3][6] - Truist Financial set a price objective of $255 for Assurant, while UBS Group raised their price target from $255 to $257, maintaining a "buy" rating [4] Group 2: Stock Performance and Market Capitalization - Assurant's stock is currently priced at $238.03, with a slight increase of 0.42%, and has fluctuated between $234.66 and $240.58 today [5][6] - The stock's year-high is $240.58, and the lowest price over the past year was $174.97, indicating significant price movement [5] - Assurant's market capitalization is approximately $11.92 billion, with a trading volume of 305,710 shares today [5][6]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Ross Stores (ROST), and emphasizes the importance of using these recommendations in conjunction with other analytical tools like the Zacks Rank. Brokerage Recommendations - Ross Stores has an average brokerage recommendation (ABR) of 1.50, indicating a consensus between Strong Buy and Buy, based on 20 brokerage firms' recommendations [2] - Out of the 20 recommendations, 15 are Strong Buy, accounting for 75% of the total recommendations [2] Limitations of Brokerage Recommendations - Solely relying on brokerage recommendations for investment decisions may not be wise, as studies show limited success in guiding investors towards stocks with the best price increase potential [5] - Brokerage firms often exhibit a positive bias in their ratings due to vested interests, leading to a disproportionate number of Strong Buy recommendations compared to Strong Sell [6][11] Zacks Rank as an Alternative - The Zacks Rank categorizes stocks into five groups based on earnings estimate revisions, providing a more effective indicator of a stock's price performance in the near future [8][12] - The Zacks Rank is distinct from the ABR, as it is a quantitative model that reflects timely earnings estimate revisions, while the ABR may not always be up-to-date [10][13] Current Earnings Estimates for Ross Stores - The Zacks Consensus Estimate for Ross Stores has increased by 4.1% over the past month to $6.43, indicating growing optimism among analysts regarding the company's earnings prospects [14] - This increase in consensus estimates, along with other factors, has resulted in a Zacks Rank 2 (Buy) for Ross Stores, suggesting a positive outlook for the stock [15]

Company Overview - Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel, involved in the development, manufacturing, and marketing of both branded and generic drugs, including biosimilars and over-the-counter products, as well as active pharmaceutical ingredients (APIs) [12] - Teva's generic product portfolio includes various forms such as tablets, capsules, liquids, ointments, creams, transdermal patches, injectables, and inhalants [12] - The company plans to separate its API unit into a standalone business unit through a sale [12] Investment Ratings - Teva is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B, indicating a solid position in the market [13] - The Value Style Score for Teva is also B, supported by attractive valuation metrics, including a forward P/E ratio of 10.22, which may appeal to value investors [13] Earnings Estimates - In the last 60 days, five analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.07 to $2.61 per share [13] - Teva has demonstrated an average earnings surprise of +7.9%, indicating a positive trend in earnings performance [13] Investment Consideration - With a solid Zacks Rank and favorable Value and VGM Style Scores, Teva is recommended to be on investors' short lists for potential investment opportunities [14]